11 Analysts Have This to Say About Mirum Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 11 Wall Street analysts have provided ratings for Mirum Pharmaceuticals (NASDAQ:MIRM), with an average price target of $60.82, which is significantly higher than the current price of $32.32. The consensus among these analysts is positive, with 3 bullish and 8 somewhat bullish ratings. However, the current average price target has decreased by 17.25% from the previous target of $73.50.
November 20, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have a positive outlook on Mirum Pharmaceuticals with a high average price target compared to the current stock price, indicating potential growth. The recent decrease in the price target may temper expectations slightly.
The positive ratings from analysts suggest confidence in Mirum Pharmaceuticals' future performance, which could lead to an increase in stock price in the short term. The decrease in the average price target might reflect a more cautious outlook but still indicates a significant potential upside.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100